Disease Landscape and Forecast 인사이트

The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…

Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…

U.S. Prescriber and Payer Perspective on Current Mainstays, Recent Launches, Late-Stage Products, and the First Generic Competitors The array of disease-modifying therapies (DMTs) approved for the…

Is There a Disconnect Between Physician and Payer Perceptions of Therapies Across Key Indications? The treatment of both solid and hematological cancers is associated with a wide range of…

Last Updated 23 October 2015 Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—…

Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and a sedentary lifestyle. The primary goal of…

Last Updated 22 October 2015 The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become…

Tackling the Market Access Challenges in Brazil, Mexico, and Argentina Increases in seroprevalent cases of hepatitis C virus (HCV), disease awareness, and patient access to HCV treatment…

For the estimated 660,000 people in the United States who suffer from ulcerative colitis (UC), there are several prescription therapies available for treating the associated symptoms. The principal…

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The expansion of the treatment labels…

This report leverages physician insights, as well as patient chart data, to provide the most up-to-date information about chronic kidney disease non-dialysis (CKD-ND) patient care in France,…

Nonalcoholic fatty liver disease (NAFLD) is caused by a buildup of fat in the liver. A proportion of NAFLD sufferers will also experience injury to their hepatocytes, which can lead to nonalcoholic…